Clarifies results of its pharmaceutical interchange program at Riverside Clinic reported in the Oct. 17 issue of "The Pink Sheet." The pilot program showed an increase in generic utilization, not formulary compliance as such. At Riverside, commercial HMO generic utilization increased to 46.5% in 1993, from 41.9% the previous year, and generic utilization in the Medicare HMO showed a similar increase, to 44.1% in 1993 from 39.7%. "The Prescription Solutions Formulary for this medical group contains primary generic as opposed to branded drugs," the company explains. The Cypress, Calif.-based company has only its mail-service operations in San Diego
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth